Cover Image
市場調查報告書

先進藥物遞輸系統的全球市場及技術-給藥途徑為焦點分析

Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration

出版商 BCC Research 商品編碼 292624
出版日期 內容資訊 英文 149 Pages
訂單完成後即時交付
價格
Back to Top
先進藥物遞輸系統的全球市場及技術-給藥途徑為焦點分析 Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration
出版日期: 2014年01月02日 內容資訊: 英文 149 Pages
簡介

藥物遞輸系統,是為了改善人體內部醫藥品的移動,能安全發揮期待的治療效果的功能,在製藥產業的繼續成長上極為重要的領域之一。製藥廠商面臨競爭加劇、專利到期、新技術登場等狀況,近幾年在這個領域有增加研究開發支出的趨勢,新的進步和新產品的投入等,可能使市場成長更加加速。先進藥物遞輸系統的市場,2013年時為1,819億美元,今後以年平均3.2%的步調繼續成長,預計2018年達到2,128億美元。

本報告提供聚焦醫藥品的給藥途徑的藥物遞輸系統全球市場概觀、今後明確預測、市場趨勢、課題、技術創新、未來的需求、法規環境、相關技術等相關分析,再加上主要企業各公司簡介,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 市場概要

  • 各種投藥形態的必要性
  • 以給藥技術為基礎分類
    • 持續放出藥物遞輸
    • 前驅藥物
    • 移植和子宮內避孕器(IUD)
    • 標靶化藥物遞輸
    • 高分子藥物遞輸
  • 以藥物遞輸系統的投藥途徑為基礎的分類
    • 口服
    • 注射及非口服
    • 鼻子
    • 口腔粘膜
    • 直腸
    • 經皮
  • 第4章 法規的各方面
  • 從2009年到2013年間已批准新產品
  • FDA的產品回收與安全性相關警告

第5章 新動向

  • 新的聯盟、合併、收購
  • 開發中產品

第6章 全球市場

  • 各種產品的市場
  • 各地區市場
  • 各種最終用途產品的市場

第7章 先進藥物遞輸系統市場分析

  • 各種給藥途徑的系統
  • 各類型市場
  • 各地區市場
  • 產業結構

第8章 專利分析

  • 從2009年1月到2013年7月已批准專利
  • 各分類的專利
  • 各類型的專利
  • 各公司的專利
  • 各國專利
  • 各申請人的專利

第9章 目前情形

第10章 主要企業簡介

  • 3M COMPANY
  • ABBOTT LABORATORIES
  • ACTAVIS INC.
  • AKELA PHARMA INC.
  • AKORN, INC.
  • ALCON INC.
  • ALEXION PHARMACEUTICALS, INC.
  • ALKERMES
  • ALLERGAN INC.
  • AMGEN INC.
  • A.P. PHARMA
  • APTALIS PHARMA INC.
  • Astellas Pharma Inc.
  • ASTRAZENECA PLC
  • ATON PHARMA
  • BAUSCH & LOMB
  • BAXTER INTERNATIONAL INC.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC
  • BIOSANTE PHARMACEUTICALS, INC.
  • BOEHRINGER INGELHEIM
  • BOSTON SCIENTIFIC
  • BRISTOL MYERS SQUIBB
  • CELGENE CORPORATION
  • CEPHALON, INC.
  • COLUMBIA LABORATORIES, INC.
  • Eisai
  • ELAN DRUG TECHNOLOGIES
  • ENZON PHARMACEUTICALS
  • GENENTECH INC.
  • GENEREX BIOTECHNOLOGY CORPORATION
  • GENZYME CORPORATION
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE PLC
  • 久光製藥
  • IMCLONE SYSTEMS INC.
  • JANSSEN BIOTECH, INC.
  • JOHNSON & JOHNSON
  • KEMPHARM, INC.
  • K.V. PHARMACEUTICAL CO.
  • LAVIPHARM CORPORATION
  • MANNKIND CORPORATION
  • MERCK & CO.
  • MYLAN LABORATORIES INC.
  • NEKTAR THERAPEUTICS
  • NEUROGESX INC.
  • NEWGEN BIOPHARMA
  • NOVARTIS AG
  • NOVAVAX, INC.
  • NOVEN PHARMACEUTICALS, INC.
  • NYCOMED US INC.
  • OSI PHARMACEUTICALS, INC.
  • PAR PHARMACEUTICAL COMPANIES, INC.
  • PDL BIOPHARMA, INC.
  • PFIZER INC.
  • QLT INC.
  • ROCHE HOLDING AG
  • SANOFI SA
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THERAJECT, INC.
  • UMEWORLD LTD.
  • VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
  • XEL PHARMACEUTICALS, INC.

第11章 附錄I

圖表清單

目錄
Product Code: PHM165A

The global revenue for advanced drug delivery systems is estimated to be $181.9 billion in 2013. In 2018, revenues are estimated to reach nearly $212.8 billion, demonstrating a compound annual growth rate (CAGR) of 3.2%.

This report provides:

  • An overview of the global market for drug delivery systems, with a focus on routes of administration.
  • Analyses of market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.
  • Discussion of the current state, setbacks, innovations, and the future needs of the market.
  • Analyses of the regulatory environment and the technology involved, including the latest developments.

STUDY OBJECTIVES

A drug delivery system is one of the very important aspects in today's growth in the pharmaceutical industry. BCC Research's goal in steering this study is to provide an overview of the current and future characteristics of the market for these drug delivery systems. The key objective is to present a comprehensive analysis and future direction of these drug delivery systems as an important tool in improving the efficacy and safety of the release of drugs in the body.

This report explores the present and future strategies within the drug delivery market, which includes sustained release drug delivery, prodrug, implants and intrauterine devices (IUDs), targeted drug delivery, polymeric drug delivery, transdermal drug delivery, and transmucosal drug delivery systems. The improvisation of the market and the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of drug delivery systems are also portrayed in this report.

A detailed analysis of drug delivery industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2013 through 2018.

Applications for drug delivery systems are also discussed in the report, with emphasis on the usage of these systems in various therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of various drug delivery systems has revealed their specific functionality in improving the transportation of a pharmaceutical compound in the body as desired to safely achieve its anticipated therapeutic effect. Modern industries have now begun to explore the advantages of these drug delivery systems in their productions and processes. This has led to the steady market for those drug delivery systems.

R&D spending, along with increasing competition, patent expiries and new technologies, are directing this in a new direction. The new advancements and new product launches have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

SCOPE OF THE STUDY

The scope of this study encompasses drug delivery systems in pharmaceutical and biotechnology markets. BCC Research analyzes each market by its type, region and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging markets for drug delivery systems include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years' of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER
10:41 2014/01/06

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, 2011-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • NEED FOR THE DOSAGE FORMS
    • TABLE 1: HISTORIC EVENTS IN DRUG DELIVERY
  • CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY
    • SUSTAINED RELEASE DRUG DELIVERY
      • Oral Sustained Release Drug Delivery
      • Intramuscular (IM) Injections or Microsyringes
        • TABLE 2: ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY
    • PRODRUGS
      • Subtypes of Prodrugs
        • TABLE 3: CLASSIFICATION OF PRODRUGS
      • Need for Prodrugs
        • TABLE 4: ADVANTAGES AND DISADVANTAGES OF PRODRUGS
  • IMPLANTS AND INTRAUTERINE DEVICES (IUDS)
    • Copper-based Devices
    • Hormonal-based Devices
    • Mechanism
      • TABLE 5: ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS
  • TARGETED DRUG DELIVERY
    • Delivery Vehicles
    • Liposomes
      • TABLE 6: ADVANTAGES AND DISADVANTAGES OF LIPOSOMES
    • Micelles and Dendrimers
    • Mechanisms of Drug Delivery
    • Advantages of Dendrimers
    • Biodegradable Particles
    • Artificial DNA Nanostructures
    • Monoclonal Antibodies
    • Applications
      • TABLE 7: ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
  • POLYMERIC DRUG DELIVERY
    • Applications of Polymers in Drug Delivery
      • TABLE 8: ADVANTAGES AND DISADVANTAGES OF POLYMERS
    • Pegylation
      • TABLE 9: ADVANTAGES AND DISADVANTAGES OF PEGYLATION
    • Future Perspectives
  • CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION
    • ORAL DRUG DELIVERY
      • TABLE 10: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
    • INJECTABLE OR PARENTERAL DRUG DELIVERY
      • TABLE 11: ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY
    • PULMONARY DRUG DELIVERY
      • TABLE 12: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
    • NASAL DRUG DELIVERY
      • TABLE 13: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
    • ORAL MUCOSAL DRUG DELIVERY
      • TABLE 14: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY
    • RECTAL DRUG DELIVERY
      • TABLE 15: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
    • OCULAR DRUG DELIVERY
      • TABLE 16: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
    • TRANSDERMAL DRUG DELIVERY
      • TABLE 17: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY

CHAPTER 4 - REGULATORY ASPECTS

  • NEW PRODUCTS APPROVED IN 2009-2013
    • TABLE 18: FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013
  • FDA RECALLS AND SAFETY ALERTS
    • TABLE 19: PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013
    • TABLE 20: SAFETY ALERTS, 2009 TO JUNE 2013

CHAPTER 5 - NEW DEVELOPMENTS

  • NEW PARTNERSHIPS, MERGERS AND ACQUISITION
    • TABLE 21: NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013
  • NEW PRODUCTS
    • TABLE 22: NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013
  • PIPELINE PRODUCTS
    • TABLE 23: PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET

CHAPTER 6 - GLOBAL MARKETS

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 24: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 1: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 25: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
      • FIGURE 2: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
    • MARKET BY REGION
    • SUSTAINED RELEASE DRUG DELIVERY SYSTEM
      • Market Overview
      • Market Revenue
        • TABLE 26: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 3: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 27: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
        • FIGURE 4: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
    • PRODRUGS
      • Market Overview
      • Market Revenue
        • TABLE 28: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 5: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 29: MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%)
        • FIGURE 6: MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%)
    • IMPLANTS AND IUDS
      • Market Overview
      • Market Revenue
        • TABLE 30: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 7: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 31: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
        • FIGURE 8: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
    • TRANSMUCOSAL DELIVERY SYSTEMS
      • Market Overview
      • Market Revenue
        • TABLE 32: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 9: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 33: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
        • FIGURE 10: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
    • TARGETED DRUG DELIVERY
      • Market Overview
      • Market Revenue
        • TABLE 34: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 11: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 35: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
        • FIGURE 12: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
    • TRANSDERMAL DRUG DELIVERY SYSTEM
      • Market Overview
      • Market Revenue
        • TABLE 36: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 13: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 37: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION, 2012 ($ MILLIONS)
        • FIGURE 14: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • POLYMERIC DRUG DELIVERY
      • Market Overview
      • Market Revenue
        • TABLE 38: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 15: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 39: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
        • FIGURE 16: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
  • MARKET BY END USERS
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 40: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 17: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 41: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
      • FIGURE 18: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)

CHAPTER 7 - MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION

  • TABLE 42: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION, THROUGH 2018 ($ MILLIONS)
  • FIGURE 19: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION, 2011-2018 ($ MILLIONS)
  • MARKET BY TYPE
    • ORAL, TOPICAL AND INJECTABLE DRUG DELIVERIES
      • Market Overview
      • Market Revenue
        • TABLE 43: GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY TYPE, THROUGH 2018 ($ MILLIONS)
        • FIGURE 20: GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY TYPE, 2011-2018 ($ MILLIONS)
  • TRANSMUCOSAL DELIVERY SYSTEMS
    • Market Overview
    • Market Revenue
      • TABLE 44: GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 21: GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
  • TRANSDERMAL DRUG DELIVERY SYSTEM
    • Market Overview
    • Market Revenue
      • TABLE 45: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 22: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • Oral, Topical, Injectables
        • TABLE 46: GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 23: GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Transmucosal Drug Delivery
        • TABLE 47: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 24: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Transdermal Drug Delivery
        • TABLE 48: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 25: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
  • INDUSTRY STRUCTURE
    • ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY
      • Market Leaders
        • TABLE 49: MAJOR MANUFACTURERS IN ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY, 2012
      • Market Share of Oral Drug Delivery
        • TABLE 50: MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012 (%)
        • FIGURE 26: MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012 (%)
      • Market Share of Injectable Drug Delivery
        • TABLE 51: MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS, 2012 (%)
        • FIGURE 27: MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS, 2012 (%)
      • Market Share of Topical Drug Delivery
        • TABLE 52: MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS, 2012 (%)
        • FIGURE 28: MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS, 2012 (%)
    • TRANSMUCOSAL DRUG DELIVERY
      • Market Leaders
        • TABLE 53: MAJOR MANUFACTURERS IN TRANSMUCOSAL DRUG DELIVERY
      • Market Share of Nasal Drug Delivery
        • TABLE 54: MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL DRUG DELIVERY, 2012 (%)
        • FIGURE 29: MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL DRUG DELIVERY, 2012 (%)
      • Market Share of Oral Mucosal/Buccal Drug Delivery
        • TABLE 55: MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY, 2012 (%)
        • FIGURE 30: MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY, 2012 (%)
      • Market Share of Rectal Drug Delivery 107
        • TABLE 56: MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY, 2012 (%)
        • FIGURE 31: MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY, 2012 (%)
      • Market Share of Ocular Drug Delivery
        • TABLE 57: MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY, 2012 (%)
        • FIGURE 32: MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY, 2012 (%)
      • Market Share of Vaginal Drug Delivery
        • TABLE 58: MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY, 2012 (%)
        • FIGURE 33: MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY, 2012 (%)
    • TRANSDERMAL DRUG DELIVERY
      • Market Leaders
        • TABLE 59: MAJOR MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012
      • Market Share
        • TABLE 60: MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 (%)
        • FIGURE 34: MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 (%)

CHAPTER 8 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 61: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
    • FIGURE 35: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
  • PATENTS BY CATEGORY
    • TABLE 62: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
    • FIGURE 36: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
  • PATENTS BY TYPE
    • TABLE 63: NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013
  • PATENTS BY COMPANY
    • TABLE 64: NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013
  • PATENTS BY COUNTRY
    • TABLE 65: NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013
  • PATENTS BY ASSIGNEE
    • TABLE 66: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013
    • FIGURE 37: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013

CHAPTER 9 - CURRENT SITUATION

CHAPTER 10 - COMPANY PROFILES

  • 3M COMPANY
  • ABBOTT LABORATORIES
  • ACTAVIS INC.
  • AKELA PHARMA INC.
  • AKORN, INC.
  • ALCON INC.
  • ALEXION PHARMACEUTICALS, INC.
  • ALKERMES
  • ALLERGAN INC.
  • AMGEN INC.
  • A.P. PHARMA
  • APTALIS PHARMA INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • ATON PHARMA
  • BAUSCH & LOMB
  • BAXTER INTERNATIONAL INC.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC
  • BIOSANTE PHARMACEUTICALS, INC.
  • BOEHRINGER INGELHEIM
  • BOSTON SCIENTIFIC
  • BRISTOL MYERS SQUIBB
  • CELGENE CORPORATION
  • CEPHALON, INC.
  • COLUMBIA LABORATORIES, INC.
  • EISAI CO., LTD
  • ELAN DRUG TECHNOLOGIES
  • ENZON PHARMACEUTICALS
  • GENENTECH INC.
  • GENEREX BIOTECHNOLOGY CORPORATION
  • GENZYME CORPORATION
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE PLC
  • HISAMITSU PHARMACEUTICAL CO., INC.
  • IMCLONE SYSTEMS INC.
  • JANSSEN BIOTECH, INC.
  • JOHNSON & JOHNSON
  • KEMPHARM, INC.
  • K.V. PHARMACEUTICAL CO.
  • LAVIPHARM CORPORATION
  • MANNKIND CORPORATION
  • MERCK & CO.
  • MYLAN LABORATORIES INC.
  • NEKTAR THERAPEUTICS
  • NEUROGESX INC.
  • NEWGEN BIOPHARMA
  • NOVARTIS AG
  • NOVAVAX, INC.
  • NOVEN PHARMACEUTICALS, INC.
  • NYCOMED US INC.
  • OSI PHARMACEUTICALS, INC.
  • PAR PHARMACEUTICAL COMPANIES, INC.
  • PDL BIOPHARMA, INC.
  • PFIZER INC.
  • QLT INC.
  • ROCHE HOLDING AG
  • SANOFI SA
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THERAJECT, INC.
  • UMEWORLD LTD.
  • VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
  • XEL PHARMACEUTICALS, INC.

CHAPTER 11 - APPENDIX I

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: HISTORIC EVENTS IN DRUG DELIVERY
    • TABLE 2: ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY
    • TABLE 3: CLASSIFICATION OF PRODRUGS
    • TABLE 4: ADVANTAGES AND DISADVANTAGES OF PRODRUGS
    • TABLE 5: ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS
    • TABLE 6: ADVANTAGES AND DISADVANTAGES OF LIPOSOMES
    • TABLE 7: ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
    • TABLE 8: ADVANTAGES AND DISADVANTAGES OF POLYMERS
    • TABLE 9: ADVANTAGES AND DISADVANTAGES OF PEGYLATION
    • TABLE 10: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
    • TABLE 11: ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY
    • TABLE 12: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
    • TABLE 13: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
    • TABLE 14: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY
    • TABLE 15: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
    • TABLE 16: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
    • TABLE 17: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY
    • TABLE 18: FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013
    • TABLE 19: PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013
    • TABLE 20: SAFETY ALERTS, 2009 TO JUNE 2013
    • TABLE 21: NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013
    • TABLE 22: NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013
    • TABLE 23: PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET
    • TABLE 24: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 25: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
    • TABLE 26: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 27: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
    • TABLE 28: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 29: MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%)
    • TABLE 30: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 31: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
    • TABLE 32: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
    • TABLE 34: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 35: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
    • TABLE 36: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 37: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION, 2012 ($ MILLIONS)
    • TABLE 38: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 39: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
    • TABLE 40: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 ($ MILLIONS)
    • TABLE 41: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
    • TABLE 42: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION, THROUGH 2018 ($ MILLIONS)
    • TABLE 43: GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 44: GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 45: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
    • TABLE 46: GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 47: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 48: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 49: MAJOR MANUFACTURERS IN ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY, 2012
    • TABLE 50: MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012 (%)
    • TABLE 51: MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS, 2012 (%)
    • TABLE 52: MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS, 2012 (%)
    • TABLE 53: MAJOR MANUFACTURERS IN TRANSMUCOSAL DRUG DELIVERY
    • TABLE 54: MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL DRUG DELIVERY, 2012 (%)
    • TABLE 55: MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY, 2012 (%)
    • TABLE 56: MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY, 2012 (%)
    • TABLE 57: MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY, 2012 (%)
    • TABLE 58: MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY, 2012 (%)
    • TABLE 59: MAJOR MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012
    • TABLE 60: MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 (%)
    • TABLE 61: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
    • TABLE 62: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
    • TABLE 63: NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013
    • TABLE 64: NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013
    • TABLE 65: NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013
    • TABLE 66: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
    • FIGURE 2: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
    • FIGURE 3: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 4: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
    • FIGURE 5: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 6: MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%)
    • FIGURE 7: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 8: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
    • FIGURE 9: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 10: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
    • FIGURE 11: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 12: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
    • FIGURE 13: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 14: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • FIGURE 15: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 16: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
    • FIGURE 17: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011-2018 ($ MILLIONS)
    • FIGURE 18: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
    • FIGURE 19: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION, 2011-2018 ($ MILLIONS)
    • FIGURE 20: GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY TYPE, 2011-2018 ($ MILLIONS)
    • FIGURE 21: GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
    • FIGURE 22: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • FIGURE 23: GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 24: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 25: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 26: MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012 (%)
    • FIGURE 27: MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS, 2012 (%)
    • FIGURE 28: MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS, 2012 (%)
    • FIGURE 29: MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL DRUG DELIVERY, 2012 (%)
    • FIGURE 30: MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY, 2012 (%)
    • FIGURE 31: MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY, 2012 (%)
    • FIGURE 32: MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY, 2012 (%)
    • FIGURE 33: MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY, 2012 (%)
    • FIGURE 34: MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 (%)
    • FIGURE 35: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
    • FIGURE 36: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
    • FIGURE 37: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013
Back to Top